NMRA · Neumora Therapeutics, Inc. · Analyst Estimates
$1.04
-0.10 (-8.77%)
At close · Sep 11
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“While the Company expects to be able to obtain additional funding, the current available cash and cash equivalents will not be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$195.41M
Shares
187.90M
Analyst Estimates
Compare analyst forecasts for Neumora Therapeutics, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Only independently verified consensus published through the company's investor-relations sources is available.
Consensus not yet available
Only independently verified consensus published through the company's investor-relations sources is available.
Key facts
CIK
1885522
CUSIP
640979100
13F (30d)
45 filings
45 filers
Visit website
Investor relations